세계의 암 표적 치료 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 치료 유형별, 적응 질환별, 최종 사용자별, 지역별 경쟁(2020-2030년)
Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By Disease Indication, By End User, By Region & Competition, 2020-2030F
세계의 암 표적 치료 시장은 2024년에 165억 5,000만 달러로 평가되었고, 2030년에는 252억 4,000만 달러에 이르고, CAGR 7.25%를 나타낼 것으로 예측됩니다.
이 시장은 암 진행에 기여하는 특정 유전자 변이, 단백질, 세포 환경에 작용하는 정밀 치료 접근에 중점을 두고 보다 광범위한 암 영역에서 중요한 부문을 형성하고 있습니다. 이 업계에는 단일클론항체, 키나아제 억제제, 면역관문억제제, 저분자 화합물 등 다양한 치료법이 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030 |
| 시장 규모 : 2024년 |
165억 5,000만 달러 |
| 시장 규모 : 2030년 |
252억 4,000만 달러 |
| CAGR : 2025-2030년 |
7.25% |
| 급성장 부문 |
유방암 |
| 최대 시장 |
북미 |
시장 성장 촉진요인
각종 암의 유병률 증가
주요 시장 과제
표적 치료와 관련된 높은 비용과 부작용
주요 시장 동향
유전체 프로파일링 및 정밀의료 진보
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 치료 유형별(호르몬 요법, 단일클론항체, 신호전달 억제제, 유전자 발현 조절제, 세포 사멸 억제제, 기타)
- 질환별(폐암, 유방암, 대장암, 백혈병, 흑색종, 림프종, 기타)
- 최종 사용자별(병원 및 클리닉, 암 및 방사선 치료 센터, 학술 및 연구 기관)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 북미 : 국가별 분석
제7장 유럽의 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 암 표적 치료 시장 전망
- 시장 규모 및 예측
- 시장 점유율 및 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 암 표적 치료 시장 : SWOT 분석
제14장 경쟁 구도
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson Service Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
제15장 전략적 제안
제16장 기업 소개와 면책사항
KTH
The Global Targeted Cancer Therapy Market was valued at USD 16.55 Billion in 2024 and is projected to reach USD 25.24 Billion by 2030, growing at a CAGR of 7.25%. This market forms a crucial segment of the broader oncology landscape, emphasizing precision treatment approaches that act on specific genetic mutations, proteins, or cellular environments contributing to cancer progression. Targeted therapies aim to maximize treatment efficacy while minimizing collateral damage often seen with traditional chemotherapy and radiation. The industry includes an array of modalities such as monoclonal antibodies, kinase inhibitors, immune checkpoint inhibitors, and small molecules. Continued innovation, R&D investment, and active clinical trial pipelines are accelerating product development, thereby fostering improved patient outcomes and expanding therapeutic possibilities across various cancer types.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 16.55 Billion |
| Market Size 2030 | USD 25.24 Billion |
| CAGR 2025-2030 | 7.25% |
| Fastest Growing Segment | Breast Cancer |
| Largest Market | North America |
Key Market Drivers
Increasing Prevalence of Various Type of Cancers
Rising cancer prevalence globally is a major force fueling the demand for targeted cancer therapies. As of 2020, cancer accounted for nearly 10 million deaths annually, making it a dominant health and economic concern. Pediatric cancer remains a high-priority area, with roughly 400,000 new diagnoses each year. Patterns of incidence vary by geography, with cervical cancer topping the list in 23 countries, reflecting inequalities in HPV vaccination and screening. This variation signals untapped markets for tailored diagnostics and therapies. Lung cancer, representing about 12.4% of all new cancer cases, remains the deadliest, contributing to 18.7% of all cancer-related fatalities. As aging populations, lifestyle shifts, and environmental exposures drive global cancer rates upward, targeted therapies provide more effective, less toxic alternatives to conventional treatments. Their ability to deliver personalized, gene-specific interventions positions them as essential tools in modern oncology, especially in light of these growing epidemiological trends.
Key Market Challenges
High Cost and Side Effects Associated with the Targeted Therapies
The considerable cost of targeted cancer treatments presents a substantial hurdle to widespread adoption. Advanced therapies such as monoclonal antibodies and gene modulators demand high manufacturing investment and specialized administration, resulting in elevated prices for patients and healthcare systems. According to the American Association for Cancer Research, the U.S. could see national cancer-related costs exceed USD 245 billion by 2030-an increase of over 30% since 2015. Patients undergoing initial, ongoing, or end-of-life cancer care can incur average annual costs ranging from USD 5,300 to over USD 41,800. This economic burden affects access to care and can lead to financial distress for both patients and healthcare providers. Additionally, while targeted therapies are generally safer than traditional chemotherapy, they are not devoid of side effects, including immune-related adverse events or organ toxicity. These challenges call for innovative cost-control strategies, reimbursement policy revisions, and research into affordable alternatives to sustain market growth.
Key Market Trends
Advancements In Genomic Profiling and Precision Medicine
The integration of genomic profiling and precision medicine is transforming cancer treatment, driving greater adoption of targeted therapies. Next-generation sequencing (NGS) and liquid biopsy technologies now enable precise identification of genetic mutations that drive cancer, allowing clinicians to tailor treatment plans based on each patient's unique tumor profile. These innovations have led to more effective, personalized therapies with fewer adverse effects. Precision medicine is also becoming instrumental in tracking disease progression and resistance patterns, enabling real-time adjustments to treatment. As these tools become more accessible, healthcare systems worldwide are increasingly implementing genomic-based protocols. This evolution in oncology practice underscores the growing reliance on targeted treatments and supports their rising use as a mainstay in cancer care strategies.
Key Market Players
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson Service Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
Report Scope:
In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Targeted Cancer Therapy Market, By Therapy Type:
- Hormone Therapies
- Monoclonal Antibodies
- Signal Transduction Inhibitors
- Gene Expression Modulators
- Apoptosis Inhibitors
- Others
Targeted Cancer Therapy Market, By Disease Indication:
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Melanoma
- Lymphoma
- Others
Targeted Cancer Therapy Market, By End User:
- Hospitals & Clinics
- Cancer & Radiation Therapy Centers
- Academic & Research Institutions
Targeted Cancer Therapy Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Targeted Cancer Therapy Market.
Available Customizations:
Global Targeted Cancer Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Targeted Cancer Therapy Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others)
- 5.2.2. By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others)
- 5.2.3. By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Targeted Cancer Therapy Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Therapy Type
- 6.2.2. By Disease Indication
- 6.2.3. By End User
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Targeted Cancer Therapy Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Therapy Type
- 6.3.1.2.2. By Disease Indication
- 6.3.1.2.3. By End User
- 6.3.2. Canada Targeted Cancer Therapy Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Therapy Type
- 6.3.2.2.2. By Disease Indication
- 6.3.2.2.3. By End User
- 6.3.3. Mexico Targeted Cancer Therapy Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Therapy Type
- 6.3.3.2.2. By Disease Indication
- 6.3.3.2.3. By End User
7. Europe Targeted Cancer Therapy Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Therapy Type
- 7.2.2. By Disease Indication
- 7.2.3. By End User
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Targeted Cancer Therapy Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Therapy Type
- 7.3.1.2.2. By Disease Indication
- 7.3.1.2.3. By End User
- 7.3.2. United Kingdom Targeted Cancer Therapy Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Therapy Type
- 7.3.2.2.2. By Disease Indication
- 7.3.2.2.3. By End User
- 7.3.3. Italy Targeted Cancer Therapy Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Therapy Type
- 7.3.3.2.2. By Disease Indication
- 7.3.3.2.3. By End User
- 7.3.4. France Targeted Cancer Therapy Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Therapy Type
- 7.3.4.2.2. By Disease Indication
- 7.3.4.2.3. By End User
- 7.3.5. Spain Targeted Cancer Therapy Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Therapy Type
- 7.3.5.2.2. By Disease Indication
- 7.3.5.2.3. By End User
8. Asia-Pacific Targeted Cancer Therapy Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Therapy Type
- 8.2.2. By Disease Indication
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Targeted Cancer Therapy Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Therapy Type
- 8.3.1.2.2. By Disease Indication
- 8.3.1.2.3. By End User
- 8.3.2. India Targeted Cancer Therapy Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Therapy Type
- 8.3.2.2.2. By Disease Indication
- 8.3.2.2.3. By End User
- 8.3.3. Japan Targeted Cancer Therapy Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Therapy Type
- 8.3.3.2.2. By Disease Indication
- 8.3.3.2.3. By End User
- 8.3.4. South Korea Targeted Cancer Therapy Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Therapy Type
- 8.3.4.2.2. By Disease Indication
- 8.3.4.2.3. By End User
- 8.3.5. Australia Targeted Cancer Therapy Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Therapy Type
- 8.3.5.2.2. By Disease Indication
- 8.3.5.2.3. By End User
9. South America Targeted Cancer Therapy Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Therapy Type
- 9.2.2. By Disease Indication
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Targeted Cancer Therapy Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Therapy Type
- 9.3.1.2.2. By Disease Indication
- 9.3.1.2.3. By End User
- 9.3.2. Argentina Targeted Cancer Therapy Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Therapy Type
- 9.3.2.2.2. By Disease Indication
- 9.3.2.2.3. By End User
- 9.3.3. Colombia Targeted Cancer Therapy Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Therapy Type
- 9.3.3.2.2. By Disease Indication
- 9.3.3.2.3. By End User
10. Middle East and Africa Targeted Cancer Therapy Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Therapy Type
- 10.2.2. By Disease Indication
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Targeted Cancer Therapy Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Therapy Type
- 10.3.1.2.2. By Disease Indication
- 10.3.1.2.3. By End User
- 10.3.2. Saudi Arabia Targeted Cancer Therapy Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Therapy Type
- 10.3.2.2.2. By Disease Indication
- 10.3.2.2.3. By End User
- 10.3.3. UAE Targeted Cancer Therapy Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Therapy Type
- 10.3.3.2.2. By Disease Indication
- 10.3.3.2.3. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Targeted Cancer Therapy Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Amgen Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. AstraZeneca plc
- 14.3. Bayer AG
- 14.4. Bristol-Myers Squibb Company
- 14.5. F. Hoffmann-La Roche Ltd
- 14.6. GlaxoSmithKline plc
- 14.7. Johnson & Johnson Service Inc.
- 14.8. Merck & Co. Inc.
- 14.9. Novartis AG
- 14.10.Pfizer Inc.
15. Strategic Recommendations
16. About Us & Disclaimer
